Podcasts about top takeaways

Dr. John Sweetenham shares highlights from Day 4 of the 2025 ASCO Annual Meeting, including new research on maintenance therapy in small cell lung cancer and a virtual reality psychosocial intervention for patients undergoing hematopoietic stem cell transplantation. Transcript Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast, with my takeaways on selected abstracts from Day 4 of the 2025 ASCO Annual Meeting. My disclosures are available in the transcript of this episode. Today's selection features reports of 3 randomized trials in very different clinical settings: maintenance therapy in extensive small cell lung cancer (SCLC), upfront surgery in advanced ovarian cancer, and a supportive care intervention for patients undergoing hematopoietic stem cell transplantation. The first of these studies, Abstract 8006, was presented by Dr. Luis Paz-Ares from the University Hospital [October 12] in Madrid, Spain, and reports the primary results of the IMforte trial. This was a phase 3 trial evaluating the combination of lurbinectedin and atezolizumab as first-line maintenance therapy in patients with extensive small cell lung cancer. Despite some improvements in the first-line treatment of extensive small cell lung cancer with the use of checkpoint inhibitors in combination with platinum-based chemotherapy, most of the patients experience early disease progression and long-term survival remains very limited. This provides a rationale for considering a maintenance intervention. Lurbinectedin is an alkylating agent and transcription inhibitor [that is] already approved in the United States for patients with relapsed/refractory metastatic SCLC following platinum-based chemotherapy. It has been shown to synergize with immune checkpoint inhibitors in pre-clinical studies and has also been evaluated in early-phase clinical trials. The IMforte trial is a global, randomized trial in which patients are initially treated with atezolizumab, and those patients who do not progress on induction therapy are then randomized to maintenance therapy with atezolizumab alone or atezolizumab with lurbinectedin. The primary endpoints of the study were progression-free and overall survival. Four hundred and eighty-three patients were randomized and at a median follow-up of 15 months, the median progression-free survival for patients who received the combination was 5.4 months and the median overall survival was 13.2 months. This compares with 2.1 and 10.6 months, respectively, in patients who received atezolizumab only. The lurbinectedin and atezolizumab combination was generally well-tolerated, with no new or unexpected safety signals. The benefit was consistent in magnitude across all the relevant patient subgroups. This is the first phase 3 study to show a progression-free and overall survivial improvement with first-line maintenance in extensive stage SCLC and the result is likely to be practice-changing, establishing a new standard of care in this tough-to-treat disease. Next up is LBA5500, presented by Dr. Sven Mahner from LMU University in Munich, Germany. This describes the results of the TRUST study, a randomized trial of upfront surgical therapy in advanced ovarian cancer. As background, total macroscopic tumor resection with maximal effort cytoreductive surgery is the cornerstone of treatment in patients with advanced ovarian cancer. The optimal timing of such surgery remains controversial, whether it's more beneficial as a primary cytoreductive surgery before chemotherapy or in the form of interval cytoreductive surgery after 3 cycles of neoadjuvant chemotherapy. Previous studies have addressed this issue, but results have been confounded by issues of patient and center selection. The TRUST study is a randomized, international, multicenter phase 3 trial that compares the outcomes of the timing of surgery in surgically fit patients with seemingly resectable FIGO stage IIIB/IVB ovarian, tubal, and peritoneal carcinoma. To ensure consistent and adequate surgical quality, participating centers in the trial were required to obtain accreditation and undergo an onsite quality assurance review. This included assessment of infrastructure, surgical proficiency, complete resection rates, and surgical volume. Seven hundred and ninety-seven patients with advanced ovarian cancer were randomized to undergo surgery prior to therapy with 6 cycles of carboplatin and paclitaxel along with bevacizumab and a PARP inhibitor, or to have the surgery between the third and fourth cycle of the same systemic therapy. Of the initial 797 patients, 688 comprised the intent-to-treat population, of whom 345 received primary cytoreductive surgery and 343 received neoadjuvant chemotherapy followed by interval cytoreductive surgery.  The results show that patients undergoing primary surgery had significantly improved progression-free survival compared with those who had interval cytoreductive surgery (median progression-free survival was 22.1 months versus 19.7 months). No difference in overall survival was observed between the 2 arms of the study.  This is the first study to show a benefit for primary cytoreductive surgery, although the progression-free survival improvement was not reflected in an overall survival difference. A subgroup analysis for patients who underwent complete cytoreduction suggests a progression-free survival and survival benefit, although it isn't clear to me that the study was powered for this endpoint. Nevertheless, these are very difficult studies to perform, and the investigators should be congratulated for this robustly conducted clinical trial. Today's final abstract is 1504, presented by Dr. Hermioni Amonoo from Harvard Medical School. The trial evaluated BMT-VR, a virtual reality psychosocial intervention for patients undergoing bone marrow transplantation. This randomized trial included adult patients undergoing autologous and allogeneic transplantation. The BMT-VR platform included, among others, modules addressing psychoeducation, coping, acceptance, and gratitude. BMT-VR patients were provided with VR headsets and completed all modules during their hospitalization. Patient-reported outcomes were then assessed at 2, 4, 12, and 24 weeks post-BMT. Use of the VR tool was tracked during hospitalization. Control patients received usual care during their hospital stay and were then assessed at the same intervals post-BMT.  Eighty evaluable patients were randomized, 39 to BMT-VR and 41 to usual care. Completion rates for the BMT-VR modules were high [at] around 70-75%.  Patients who received the BMT-VR intervention experienced significantly improved anxiety, quality of life, and coping at 4 weeks post-BMT. In the longer term, sustained benefits were seen at 24 weeks for some endpoints including quality of life, with some benefits, including for depression and PTSD symptoms, improving longitudinally over the study period. These data are preliminary and will need to be confirmed in larger multicenter studies, but this trial demonstrates the feasibility of using virtual interventions in our patients and also provides intriguing preliminary data that they may be effective. Thanks for listening to today's report and I hope you will join me again tomorrow to hear more top takeaways from the final day of ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.     Find out more about today's speaker:     Dr. John Sweetenham       Follow ASCO on social media:      @ASCO on Twitter     @ASCO on Bluesky     ASCO on Facebook     ASCO on LinkedIn       Disclosures:    Dr. John Sweetenham:     No relationships to disclose 

Dr. John Sweetenham shares highlights from Day 3 of the 2025 ASCO Annual Meeting, including new research for the treatment of advanced renal cell carcinoma and 2 studies on novel approaches in non-small cell lung cancer. Transcript Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast, with my takeaways on selected abstracts from Day 3 of the 2025 ASCO Annual Meeting. Today's selection features studies addressing the treatment of advanced renal cell carcinoma and 2 studies exploring novel approaches in non-small cell lung cancer. My disclosures are available in the transcript of this episode. The first abstract is number 4505. This study, led by Dr. Toni Choueiri of the Dana-Farber Cancer Institute, describes the final analysis of the CheckMate 214 trial, which compared the combination of nivolumab and ipilimumab with sunitinib for the first-line treatment of advanced renal cell carcinoma. The ipi-nivo combination is approved for the frontline treatment of intermediate and poor-risk advanced renal cell carcinoma based on the primary analysis of the CheckMate 214 trial, which demonstrated a higher response rate and longer overall survival compared with sunitinib. Today's presentation provided the final safety and efficacy results for the trial with long-term follow-up of more than 9 years.  The intent-to-treat (ITT) population in this trial comprised 550 patients randomized to nivo and ipi versus 546 who received sunitinib. The final analysis showed sustained long-term benefit for the combination therapy. Patients given nivolumab plus ipi had a 29% reduction in the risk for death compared with sunitinib. For patients with intermediate or poor-risk disease, there was a 31% reduction in the risk of death.   The probability of remaining in response through 8 years was more than doubled with nivolumab plus ipilimumab versus sunitinib in the ITT population at 48% versus 19%, and in the intermediate and poor-risk population at 50% versus 23%. The other important observation is that patients with favorable-risk disease appeared to have a 20% reduction in the risk for death at 9 years and more durable responses. This suggests a possible delayed benefit for ipi and nivo in this group since these differences were not seen in the earlier analysis.   No new safety signals emerged with longer follow-up, and the results confirm the use of ipi and nivo as a standard front-line combination therapy in this disease. Since this combination has been in widespread use for some years, the results are not surprising although the subgroup analysis suggesting benefit in favorable-risk patients is likely to inform practice in the future.   Today's second abstract is number is 8506, which was presented by Dr. Tony Mok from the Chinese University of Hong Kong, describing results from the phase 3 HERTHENA-Lung02 trial. This trial compared the antibody-drug conjugate patritumab deruxtecan with platinum-based chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer following a third-generation tyrosine kinase inhibitor (TKI).  Patritumab deruxtecan, also known as HER3-DXd, comprises a fully human anti-HER3 IgG3 monoclonal antibody conjugated to a topoisomerase 1 inhibitor payload, and showed activity in a previous phase 2 trial in patients relapsing after EGFR TKI and chemotherapy.   In this phase 3 study, this agent was compared with platinum-based chemotherapy in eligible patients with an EGFR-activating mutation who had previously received 1 or 2 EGFR TKIs, at least one of which was a third-generation drug, with relapse or progression after this therapy. Five hundred and eighty-six patients were enrolled, with progression-free survival as the primary endpoint.  The primary analysis showed a 9-month progression-free survival of 29% for the experimental arm compared with 19% for platinum-based chemotherapy, for a hazard ratio of 0.77 and a P value of 0.011. With higher progression-free survival rates at 6 months and 12 months, HER3-DXd also had a better objective response rate (35.2% versus 25.3%) compared with platinum-based chemotherapy (PBC), and HER3-DXd also extended intracranial progression-free survival compared with PBC in patients with brain metastases, with a hazard ratio of 0.75. Grade 3 or more treatment-related adverse events occurred in 73% of patients treated with HER3-DXd and 57% of patients who received PBC. HER3-DXd had a higher rate of grade or more 3 thrombocytopenia, and drug-related interstitial lung disease occurred in 5% of patients in the HER3-DXd arm.   The follow-up will need more time to mature since no overall survival data are currently available, but definitely an agent to watch with interest. Moving on to today's final abstract, 8500, was presented by Dr. Pasi Jänne from the Dana-Farber Cancer Institute, describing results from the phase 2 portion of the KRYSTAL-7 study. This study is exploring the use of a potent KRAS inhibitor, adagrasib, in combination with pembrolizumab in patients with advanced or metastatic KRASG12C- mutated non-small cell lung cancer.  Adagrasib has already received accelerated approval in the U.S. for previously treated locally advanced or metastatic NSCLC with a KRASG12C mutation. A previous report from the KRYSTAL-7 study demonstrated encouraging activity in combination with pembrolizumab in the frontline setting for this patient group who also had more than 50% expression of PD-L1. The presentation today described efficacy and safety data for this drug combination across all PD-L1 expression levels.  One hundred and forty-nine patients with a median age of 67 years were treated with the combination, 104 of whom had PD-L1 expression level results available, representing the so-called biomarker population in this trial. The overall response rate for the entire study population was 44%. In the biomarker population, the overall response rate ranged from 36% in those with less than 1% PD-L1 expression to 61% for those with more than 50% expression. For all patients, the median response duration was just over 26 months, and the median progression-free and overall survival rates were 11 and 18.3 months respectively.    For the biomarker population, the median progression-free and overall survival were highest in those patients with more than 50% PD-L1. No new safety issues emerged from this analysis; the most frequent toxicities were nausea, diarrhea, and increases in transaminases. Immune-related toxicities included pneumonitis, hypothyroidism, and hepatitis. These are important results and the results of the phase 3 portion of KRYSTAL-7, which compares first-line therapy with adagrasib plus pembro versus pembro alone in the KRASG12C mutated/PD-L1 more than 50% group, will be informative. For those patients with lower levels of PD-L1 expression, the authors suggest that the treatment escalation may be beneficial, possibly including the addition of chemotherapy.  That concludes today's report. Thanks for listening and I hope you will join me again tomorrow to hear more top takeaways from ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.  Disclaimer:  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  Find out more about today's speaker:    Dr. John Sweetenham    Follow ASCO on social media:     @ASCO on Twitter    @ASCO on Bluesky    ASCO on Facebook    ASCO on LinkedIn     Disclosures:   Dr. John Sweetenham:    No relationships to disclose

Dr. John Sweetenham shares highlights from Day 2 of the 2025 ASCO Annual Meeting, including new data on the treatment of ER+/HER2-negative breast cancer and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high risk of recurrence.  Transcript Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, your host of the ASCO Daily News Podcast, welcoming you to our special coverage of the 2025 ASCO Annual Meeting. Today, I'll be bringing you my takeaways on selected abstracts from Day 2 of the Meeting. My disclosures are available in the transcript of this episode.  Today's selection features important, new data on the treatment of ER-positive, HER2-negative breast cancer, the use of tumor treating fields in combination with chemotherapy for locally advanced pancreatic cancer, and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high-risk of recurrence.  Our first selected abstract is LBA1000. This important phase 3 study was presented by Dr. Erika Hamilton from the Sarah Cannon Research Institute in Nashville and evaluated the use of a novel agent, vepdegestrant, in patients with ER-positive/HER2-negative breast cancer, which had progressed after first-line endocrine therapy. Vepdegestrant is a selective oral PROTAC estrogen receptor degrader, which targets wild-type and mutant estrogen receptor through a novel mechanism of action which directly harnesses the ubiquitin-proteasome system to degrade ER. It has potential advantages over fulvestrant, a selective ER degrader which has to be administered intramuscularly and has limited benefit in patients who progress after endocrine therapy plus a CDK4/6 inhibitor.  Building on the encouraging results from the initial phase 1/2 study of vepdegestrant, Dr. Hamilton reported results from the VERITAC-2 global phase 3 trial, comparing this agent with fulvestrant. The patients in the study had already received treatment with hormone therapy and a CDK inhibitor and were randomly assigned to receive treatment with either vepdegestrant (313 patients) or fulvestrant (311 patients). The vepdegestrant was taken orally each day, while the fulvestrant was given intramuscularly on days 1 and 15 of the first cycle of treatment and day 1 of each subsequent treatment cycle. Patients were stratified by the presence of wild-type ER or ESR1 mutation. A total of 43.3% of patients had ESR1 mutations; 136 of those were in the vepdegestrant group and 134 in the fulvestrant group.   For patients with ESR1 mutations, vepdegestrant significantly increased progression-free survival compared with fulvestrant. For patients who received vepdegestrant, the median PFS was 5 months versus 2.1 months for those who received fulvestrant. The clinical benefit rate was 42.1% in the vepdegestrant group vs. 20.2% in the fulvestrant group. The overall response rate was 18.6% in the vepdegestrant group compared with only 4% in the fulvestrant group.  The PFS and response benefits of vepdegestrant were largely restricted to the population with ESR1 mutations. Overall survival data are currently immature. The safety profile was favorable, with fewer than 5% of patients having dose reductions or discontinuation due to toxicity. The most frequent toxicities were fatigue, nausea, and elevated transaminases.  The authors concluded that oral vepdegestrant demonstrates statistically significant and clinically meaningful improvement in progression-free survival compared with fulvestrant in this group of patients with ESR1-mutated ER+/HER2- advanced breast cancer who have progressed after endocrine therapy and a CDK inhibitor. Patients with recurrent disease in this context are now routinely tested for ESR1 mutations, and this agent is for sure a potential treatment option for them.  The next study on today's episode, LBA4005, reports on the use of tumor treatment fields for patients with locally advanced pancreatic cancer. Tumor treatment fields are electric fields which disrupt cell division and may also induce an enhanced immune response, using a non-invasive portable device attached to the skin, and are already approved for the treatment of some cancers, including GBM and non-small cell lung cancer. A previous phase 2 trial, PANOVA-2, confirmed the feasibility and safety of using this approach in combination with gemcitabine plus or minus nabpaclitaxel in pancreatic cancer. In today's presentation, Dr. Vincent Picozzi from the Virginia Mason Medical Center in Seattle presented the results of the PANOVA-3 trial, a phase 3 study comparing gemcitabine and nabpaclitaxel with the same chemotherapy plus tumor treatment fields in patients with locally advanced pancreatic adenocarcinoma.  Five hundred and seventy-one eligible patients were enrolled in the study with a total of 405 (198 in the treatment field group and 207 in the standard arm) comprising the modified intent- to-treat population. The duration of chemotherapy treatment was comparable in both study arms, and patients receiving treatment fields had a median exposure of almost 27 weeks.  Statistically significant improvements were observed for several study endpoints, including overall survival (a median of 16.2 versus 14.2 months), distant PFS (at 13.9 versus 11.5 months) and pain-free survival (at 15.2 versus 9.1 months), all in favor of the treatment fields arm. Although quality of life data were not reported in detail, the authors noted a significant improvement in global health status in the treatment fields arm. Safety data showed a higher level of skin adverse events in the treatment fields arm but were otherwise as expected for the GnP combination.  These are quite remarkable results which add to the growing evidence base for tumor treatment fields and are particularly compelling in this patient group given the substantial improvement in pain-free survival. It will be especially interesting to see the mature analysis of the quality-of-life endpoints in a subsequent report.  The final selection today is Abstract 6001, which describes the C-POST trial, a phase 3 trial of adjuvant cemiplimab versus placebo in patients with high-risk cutaneous squamous cell carcinoma of the skin. This study was presented by Dr. Danny Rischin from the Peter MacCallum Cancer Centre in Melbourne, Australia.   Although surgical resection with or without adjuvant radiation is curative in 90% of patients with cutaneous squamous cell carcinoma, high-risk features, including nodal disease, skin and subcutaneous metastases, perineural invasion and bone involvement, predict for an inferior prognosis.  Cemiplimab, a PD-1 targeting antibody is standard therapy for patients with locally advanced or metastatic disease who are not candidates for curative surgical resection or radiation therapy, with an overall response rate of almost 50%.  The C-POST study evaluated the use of cemiplimab as adjuvant therapy following surgery and radiation in high-risk patients, compared with placebo. Treatment was administered at 3-week intervals for 12 weeks, and then 6-week intervals for a further 36 weeks, with a primary endpoint of disease-free survival. Four hundred and fifteen patients were randomized in the study, 209 to cemiplimab and 206 to placebo. With median follow-up at 24 months, Dr. Rischin reported a highly significant improvement in disease-free survival for the cemiplimab arm, 49.4 months for placebo versus not reached for cemiplimab, with improvements also observed in the rates of locoregional recurrence and distant recurrence at 80% and 60% reductions, respectively. No new safety signals were observed.  This study is potentially practice-changing and provides strong evidence that cemiplimab should be considered the new standard of care in this clinical context.  Thanks for listening today and join me again tomorrow to hear more top takeaways from ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.  Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speaker:   Dr. John Sweetenham   Follow ASCO on social media:    @ASCO on Twitter   @ASCO on Bluesky   ASCO on Facebook   ASCO on LinkedIn    Disclosures:   Dr. John Sweetenham:   No relationships to disclose  

The San Francisco 49ers kicked off OTA's today and thus were sharing the latest takeaways from the practice including the return of Christian McCaffrey, Ricky Pearsall's injury and the first glimpse of Brock Purdy after signing a massive contract extension.Plus, we reveal some key absences and detail some of the days winners and including Jacob Cowing, Renardo Green and Mykel Williams.

In the first episode of a special daily series during the 2025 ASCO Annual Meeting, Dr. John Sweetenham discusses the results of 2 studies on the treatment of advanced colorectal cancer plus an additional study exploring the association of Medicaid expansion with cancer survival outcomes. Transcript Dr. John Sweetenham: Hello, and welcome to our special coverage of the 2025 ASCO Annual Meeting on the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'll be bringing you brief analysis on selected abstracts from each day of the Meeting. My disclosures are available in the transcript of this episode.  Today, I'll be reviewing three abstracts, the first two of which address the treatment of advanced colorectal cancer. Today's first study is Abstract 3501. These data were presented by Dr. Heinz-Josef Lenz from the USC Norris Comprehensive Cancer Center and report on the expanded analysis of the CheckMate-8HW trial. This was a phase 3, international, multicenter trial in patients with MSI-high/MMR-deficient metastatic colorectal cancer, who were randomized between nivolumab (nivo) alone, nivolumab plus ipilumomab (ipi) or investigators' choice of chemotherapy (FOLFOX or FOLFIRI) with or without bevacizumab or cetuximab. The study showed that nivo plus ipi demonstrated superior progression-free survival compared with chemotherapy in the first-line setting and superior progression-free survival compared with nivo alone across all lines of therapy. These results led to the approval of nivo + ipi in the first-line setting in patients with MSI-H/dMMR mCRC in the U.S., the EU, and many other countries.  In today's presentation, Dr. Lenz reported on the expanded analyses of nivo plus ipi versus nivo across all lines of therapy and longer follow-up results for nivo and ipi versus chemo in the first-line setting. With longer follow up (the median is now at 47 months) nivo and ipi continued to show progression-free survival benefit compared with chemotherapy with a median PFS of 54.1 months versus 5.9 months, for a hazard ratio of 0.21.  Additionally, the analysis of the effects on PFS2, defined as the time from randomization to progression after subsequent systemic therapy, start of second subsequent systemic therapy, or death, showed that compared with chemotherapy, first-line nivo and ipi was associated with a 72% reduction in the risk of death or disease progression, despite the fact that 71% of those who progressed following chemotherapy crossed over to receive subsequent immunotherapy. The study also showed that across all lines, nivo and ipi demonstrated superior progression-free survival compared with nivo alone, the median not reached versus 39.3 months, for a hazard ratio of 0.62. No new toxicity signals emerged after further analysis. Most treatment-related adverse events with possible immune etiology were observed within the first six months of therapy. The results for PFS2 are particularly significant. Up to now, there has been some reluctance to use nivo and ipi as first-line therapy, partly because of its toxicity profile and based on the rationale that it would be active after other frontline therapies. The observation in this study that the beneficial effects of nivo and ipi are maintained downstream is compelling. The results suggest that delaying the use of this combination to the second line or later may compromise subsequent PFS and supports the use of nivo and ipi as a standard-of-care frontline option for MSI-H/dMMR metastatic colorectal cancer. Moving on, the next study I'm featuring today is Abstract 3503, presented by Dr. Jeanne Tie from the Peter MacCallum Cancer Centre and the Walter and Eliza Hall Medical Institute of Medical Research from Melbourne, Australia. This study reported the impact of circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy escalation in stage III colon cancer, focused on the primary analysis of the ctDNA-positive cohort from the randomized DYNAMIC-III trial. As background, about 30% of patients with stage III colon cancer will recur following standard-of-care adjuvant therapy with oxaliplatin-based regimens. And current data show that for those patients with high-risk disease, 6 months of chemotherapy is associated with a lower recurrence rate than 3 months. Circulating tumor DNA following initial surgery has been shown to be a strong independent prognostic factor for these patients, but questions remain about how ctDNA can be used for adaptation of treatment. Questions regarding treatment adaptation were addressed in the DYNAMIC-III trials – specifically, does treatment escalation benefit those who are ctDNA positive following surgery, and can therapy be de-escalated for those who are ctDNA negative. The first of these 2 questions – treatment escalation in the positive group – is the subject of this report. One thousand and two patients were randomized in this study, between ctDNA-informed therapy (502) or standard management (500). Of those patients included in the intent to treat cohorts, 129 were ctDNA positive in the ctDNA-informed arm compared with 130 in the standard management arm. Various pre-planned treatment escalation protocols were used, depending on the choice of first-line therapy. With a median follow up of 42.2 months, there was no difference in 3-year relapse free survival between the ctDNA informed group (48%) and the standard management group (52%). There was, however, a highly significant difference in relapse-free survival for patients who cleared ctDNA by the end of treatment compared with those who didn't. The authors concluded that the recurrence risk for this group remains high, at about 50%, after adjuvant therapy and that it increases with higher ctDNA burden, but treatment escalation didn't appear to reduce the recurrence risk. Clearance of ctDNA was associated with a favorable outcome, suggesting that as more effective treatments are developed in the future for this group, ctDNA will likely prove to have major utility. Changing gears now, my final selection for today is Abstract 11006, presented by Dr. Elizabeth Shafer from the American Cancer Society. This study explored the association of Medicaid expansion with 5-year survival after a cancer diagnosis.  Dr. Schafer began her presentation by providing some historical perspective on the impact of the Affordable Care Act on reducing the number of uninsured adults aged less than 65 years in the United States. She then reviewed some recent data on the impact of Medicaid expansion on cancer care, including improved screening rates, improved access to cancer surgery, and an increase in earlier cancer diagnosis. The current study builds on earlier data from the American Cancer Society which showed improved 2-year overall survival for patients with newly diagnosed cancer following Medicaid expansion. The new study reported by Dr. Schafer examined 5-year cause-specific survival in individuals with cancer since Medicaid expansion, analyzed according to cancer type and various demographic and social factors. Using data from more than 813,000 individuals from 26 states that expanded Medicaid compared with more than 610,000 from 12 states that did not, the authors reported that similar improvements in 5-year cause-specific survival were observed in the expansion and the non-expansion states, but when analyzed by other factors, differences in outcome emerged. For example, although similar improvements in survival between expansion and non-expansion states were seen in urban communities, there was a significant improvement of 2.55 percentage points in survival for individuals in rural communities in expansion states compared with those in non-expansion states. Similar trends were observed in high poverty areas, where improvements in survival were superior in expansion versus non-expansion states.  When examined by cancer type, the authors observed greater improvements in 5-year survival for those with pancreatic, lung, and colorectal cancer, possibly due to improvements in screening and early access to treatment.  The authors concluded that those residing in rural and high-poverty areas experienced the most improvement in cause-specific cancer survival following Medicaid expansion. In summary, it's encouraging to see an improving trend in cancer mortality overall, independent of Medicaid expansion, but it's also important to remember that this is yet another study which confirms how implementation of the ACA has improved cancer outcomes and begun to address some of the disparities in cancer care. Join me again tomorrow to hear more top takeaways from ASCO25. And if you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.     Find out more about today's speaker:  Dr. John Sweetenham    Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn        Disclosures:  Dr. John Sweetenham:  No relationships to disclose 

In this episode of RNT Fitness Radio, we sit down with Professor Jane Ogden, a leading health psychologist and professor at the University of Surrey. With over three decades of research in eating behavior, weight management, and women's health, Jane has been at the forefront of understanding the psychological drivers behind our relationship with food. Her expertise dives deep into the learned associations, cultural influences, and individual perceptions that shape our eating habits. Join us as we explore the psychology of eating, the barriers to sustainable weight loss, and practical strategies for long-term health transformation.   Chapters: 00:00 Introduction to Health Psychology and Eating Behavior 02:35 The Complexity of Hunger and Eating Triggers 04:37 Understanding Emotional and Social Eating 10:18 The Importance of Meal Structure 12:39 Intuitive Eating vs. Structured Eating 17:58 Navigating Social Pressures and Eating Choices 20:47 Navigating Truth and Lies in Self-Care 22:20 Psychological Barriers to Healthy Living 24:48 The Impact of Childhood Food Associations 26:06 The Evolution of Nutritional Advice 28:01 Breaking the All-or-Nothing Mindset 30:59 Sustainable Caloric Restriction Strategies 32:05 The Importance of Planned Eating 34:23 Managing Emotional Eating Through Planning 36:42 The Role of Biology vs. Psychology in Weight Loss 37:39 Top Takeaways for Managing Eating Behaviors   Next steps:  1) Apply for 1-1 coaching: https://www.rntfitness.co.uk/pro/   2) Take our quiz to see if you're ready for a transformation: http://www.rntfitness.co.uk/transform   3) Get our free book shipped to your door: https://bit.ly/tybtylform   4) Try our free 28 day fat loss accelerator: https://www.rntfitness.co.uk/transformation-accelerator  5) Optimum Nutrition: RNT20 for 20% off Connect with RNT Fitness:  Website  Facebook  Instagram  YouTube  Email  Connect with Akash:  Facebook  Instagram  LinkedIn 

Thinking about playing football at the next level? In this episode of The Gametime Guru Podcast, we dive deep into the real-life journey of Carl Pickens, from high school standout to Freshman All-American at Tennessee, to NFL Offensive Rookie of the Year with the Cincinnati Bengals. This conversation is essential listening for:

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Matt Benelli sits down with sales veteran and Calm Ocean Sales founder Mike Muhlfelder for a no-BS conversation every CRO and sales leader needs to hear. With three decades of experience at companies like Oracle, IBM, and Jitterbit, Mike shares his unfiltered perspective on what's gone wrong in modern B2B sales from bloated pipelines and broken qualification processes to tech stacks that mask, rather than solve, performance problems. If you're relying on BANT and 4x pipeline math to hit your number, Mike says it's time to wake up.Listeners will learn why great reps don't always make great leaders, how to use the “Four W's” to qualify real opportunities, and why many teams are scaling mediocrity with automation. Mike also offers hard-won advice for CROs under boardroom pressure, and a stark reminder to protect your health and values as you chase performance. It's part strategy, part therapy, and all signal, no noise.Top Takeaways 1. Great salespeople don't always make great sales leaders.Mike challenges the myth that success as a rep naturally translates to leadership, emphasizing that leading a team requires a completely different skillset.2. Stop promoting outsiders into sales leadership roles.Bringing in non-sales professionals to run sales teams often fails because they lack the experiential knowledge and empathy to lead sellers effectively.3. Sales is a profession and must be treated like one.Like finance or engineering, sales requires continuous training, discipline, and a commitment to mastery, not just charisma or improvisation.4. Outdated qualification methods like BANT hurt your deals.BANT is adversarial and obsolete; it leads to mistrust and surface-level qualification instead of real discovery.5. Use the ‘Four W's' to qualify deals more accurately.Mike's framework: What happened? Why now? Who owns the project? When do they need to be live? Creates human-centered, business-grounded qualification.6. The pipeline problem is systemic, not just executional.Teams rely on inflated pipelines and 4–5x coverage ratios because poor qualification and forecasting have become normalized.7. Most sales tech stacks enable mediocrity at scale.Without sound fundamentals, even the best tools just help teams do the wrong things faster.8. Sales math still matters: maximize yield, minimize waste.Effective revenue leaders think like manufacturers, optimizing the fewest inputs (leads) for the highest output (closed deals).9. Salespeople must take ownership of their own development.With unlimited learning resources available, Mike urges reps to stop waiting for enablement and start taking personal accountability.10. CROs must prioritize clarity, courage, and communication.From cleansing the pipeline to resetting board expectations, Mike says leadership means telling hard truths and doing the right thing even when it's unpopular.11. Burnout is real, and it's not worth it.He ends with a human message: no job is worth sacrificing your health, family, or identity, no matter how big the number.

Ray and JRich break down everything you need to know from NFC Rookie Mini Camps—highlighting which first-year players already stand out across the league. From top draft picks to under-the-radar names, we're tracking:

We're breaking down all the biggest stories and early standouts from AFC Rookie Mini Camps! Ray and JRich go team-by-team highlighting the rookies who are already making noise, adjusting quickly, or flashing long-term potential. From first-round picks to late-round sleepers, we're tracking who's turning heads and which storylines matter most.

“If I go to the good Hopi Indian quote, ‘We don't inherit the earth from our ancestors, we borrow it from our children.' I sit in reflection of that and I hope the future generations will lead with heart and they'll be guided by the values that built this legacy to date. That they honor the past by innovating with purpose and with integrity. Everybody's always got to remember that stewardship is a sacred trust, and one that turns heritage into hope.”We're in great company with Shan and Bronwyn Varty, the mother and daughter duo behind Londolozi, who, with their family's one hundred years of history, are pioneering one of South Africa's original private game reserves as a living model of conservation development. Here, they are nurturing a Futuristic African Village, a prototype for village consciousness where wild animals and people alike, live together in dignity and harmony, with each other and the land. It is with an abundance mindset that they have chosen to share this land and legacy with worldly guests, committing to excellence in ecotourism with their accredited Relais & Châteaux status. In celebration of Mother's Day, in this episode, Shan and Bron paint for us a picture of luxury in its purest form—with time as the artist, the senses as the medium, and Mother Nature as the muse. Top Takeaways[2:10] With 100 years of family history living on this land, the Varty's roots run deep and strong as they grow and evolve with their environment.[4:50] The name Londolozi is Zulu for ‘Protector Of All Living Things,' reflecting their ambitious conservation ethic in stewarding our human relationship with the natural world. [7:00] They say “it takes a village to raise a child,” and there is sincere truth in that there is a power of resilience in community, as both Shan and Bron learned early on. [12:30] “When you live in nature, you live in an ecosystem of connection, not comparison.”[15:15] How meditative design is a way of practicing presence, learning to get out of the way and allow nature to lead, creating a sense of place that meets you where you are. [20:00] Londolozi's Camps are a collection woven together with a “Golden Thread”—each with their own significance, but all along a journey through legacy and luxury. [29:15] The Varty's are proud “Artists of Experiences”—curating luxury safaris for every chapter of life—from first-time safaris to multigenerational family trips, from honeymoons to wellness, with photography and more in store,[36:40] The “Ripple Effect” stands for Restoration, Innovation, Protection, People, Leadership, Education.[41:00] Rather than creating something new, Shan and Bron are celebrating 100 years of history by bringing back the old, polishing and preserving along the way.[46:15] Mother Nature's wisdom is in embracing a state of flow that changes with the seasons—recognizing that mothering is not something that is done, it is something that is felt—and can only be done so by slowing down. Notable MentionsNelson MandelaMaya AngelouThe Leopards of LondoloziPeter Reed LinensLand RoverSesaties, South African Kebabs Good Work FoundationTracker Academy Healing HouseVisit For YourselfLondolozi Website | @londoloziImages courtesy of Londolozi Game Reserve

Tommy Scoops is back with a vengeance ready to dive into all the biggest MLS talk like Mikal Bridges defending a last second shot. Gass and Tom dig into LAFC's Club World Cup hopes being brought back, your big questions from the MLS weekend, and of course an incredible upcoming round of USOC with some big Cupset potential.11:20 LAFC Club World Cup Play In Chance26:30 MLS Weekend Takeaways26:50 Austin FC Offensive Struggles31:15 Philly Center Mid Strength35:20 Revs Formation Change Success40:00 Top Homegrown Breakthroughs So Far In 202547:35 Vanney & LAG Struggles55:25 USOC Round Of 32 Preview1:05:48 Ice Cream Shop On KDB, Mueller & Some Homegrown Signings Soccerwise Live 2pm ET Every Tuesday/Wednesday/Thursday on Youtube/Twitch/Twitter

In the latest episode of the “Connecting the Dollars” podcast, Amanda Vaught and guest David Vaught CFA dive deep into Warren Buffett's 2025 Berkshire Hathaway annual letter. If you're keen on strategy, leadership, or simply fascinated by Buffett's approach, this episode is a must-listen.

"Breathe light to breathe right. It's not about taking big breaths — it's about breathing less, through your nose." – Patrick McKeownIn this solo episode of Talk Healing to Me, host Karen Dwyer shares her top 10 takeaways from her life-changing conversation with world-renowned breathing expert Patrick McKeown. From anxiety and panic to fatigue, brain fog and chronic pain, breathwork is the tool many of us overlook — and it's free.Karen unpacks simple but powerful techniques Patrick shared that can immediately shift your nervous system, improve sleep, and calm your mind. Whether you're living with MS or simply overwhelmed by stress, this episode will teach you how to breathe better so you can feel better.In This Episode, You'll Learn:

"There were four things that I thought were really important. The first one was to be humble and confident. Number two, be open-minded, but have a point of view. The third point was to know there is no substitute to working hard. Last but not least was to embrace change and challenges.”We're in great company with Sylvia Wong, the Owner of The Roundtree Amagansett, where she meticulously polished a hidden gem into an award-winning luxury boutique hotel in the heart of the Hamptons that pays homage to Amagansett's historic farmsteading legacy while embodying the spirit of this iconic east coast destination.Her journey from corporate law executive to passionate first-time hotelier exemplifies a dream transformation—inspired by her global travels to create a rarefied Hampton's experience where guests can truly live like locals.In this episode, Sylvia shares her inspiring career pivot, the challenges of opening during a pandemic, and how she crafted an authentic home-away-from-home experience that keeps guests returning season after season.Top Takeaways[1:40] How Sylvia's corporate career took her to hidden corners of the world where she embraced diverse cultural expressions through architecture and design and found a motherly instinct for nurturing guest experiences. [5:05] It all began with a single raised hand in a meeting, a serendipitous stop on the Jitney shuttle, and Sylvia's unwavering determination to master the art of hospitality—despite having no industry experience whatsoever.[9:30] Steps from Main Street, Sylvia discovered an unassuming property with centuries of stories hidden beneath its weathered shingles and expansive grounds.[17:20] At The Roundtree Amagansett, luxury whispers rather than shouts—as guests discover thoughtful complimentary amenities designed to create moments of surprise and delight from sunrise to starlight. [30:40] Why Sylvia's sense of fulfillment is not found through financial means—it is in seeing genuine happiness wash over her guests' faces as they share their stories and experiences.[34:40] There is much creativity and collaboration yet to come—from new culinary offerings to seamless wellness incorporations to thoughtfully designed spaces where families and friends can gather to create their own Hampton traditions for generations to come.Notable Mentionsil Buco al MareBalsam FarmsAmber Waves Farm, Market & CafeLongHouse ReserveParrish Art MuseumSouth Fork BakeryFrette linens & Matouk towelsThe Maker fragrances RUMOR Rosé Wölffer Estate VineyardThe Chanler at Cliff Walk, Rhode IslandVisit For YourselfThe Roundtree Amagansett Website | @theroundtreeamagansett

Jodi Daniels is the Founder and CEO of Red Clover Advisors, a privacy consultancy, that integrates data privacy strategy and compliance into a flexible, scalable approach that simplifies complex privacy challenges. A Certified Information Privacy Professional, Jodi brings over 27 years of experience in privacy, marketing, strategy, and finance across diverse sectors, working and supporting startups to Fortune 500 companies. Jodi Daniels is a national keynote speaker, and she has also been featured in CNBC, The Economist, WSJ, Forbes, Inc., and many more publications. Jodi holds a MBA and BBA from Emory University's Goizueta Business School. Read her full bio. Justin Daniels is a corporate attorney who advises domestic and international companies on business growth, M&A, and technology transactions, with over $2 billion in closed deals. He helps clients navigate complex issues involving data privacy, cybersecurity, and emerging technologies like AI, autonomous vehicles, blockchain, and fintech. Justin partners with C-suites and boards to manage cybersecurity as a strategic enterprise risk and leads breach response efforts across industries such as healthcare, logistics, and manufacturing.  A frequent keynote speaker and media contributor, Justin has presented at top events including the RSA Conference, covering topics like cybersecurity in M&A, AI risk, and the intersection of privacy and innovation. Together, Jodi and Justin host the top ranked She Said Privacy / He Said Security Podcast and are authors of WSJ best-selling book, Data Reimagined: Building Trust One Byte at a Time. In this episode… From a major privacy summit to a regional AI event, experts across sectors are emphasizing that regulatory scrutiny is intensifying while AI capabilities and risks are accelerating. State privacy regulators are coordinating enforcement efforts, actively monitoring how companies handle privacy rights requests and whether cookie consent platforms work as they should. At the same time, AI tools are advancing rapidly with limited regulatory oversight, raising serious ethical and societal concerns. What practical lessons can businesses take from IAPP's 2025 Global Privacy Summit and Atlanta's AI Week to strengthen compliance, reduce risk, and prepare for what's ahead? At the 2025 IAPP Global Privacy Summit, a major theme emerged: state privacy regulators are collaborating on enforcement more closely than ever before. When it comes to honoring privacy rights, this collaboration spans early inquiry stages through active enforcement, making it critical for businesses to establish, regularly test, and monitor their privacy rights processes. It also means that companies need to audit cookie consent platforms regularly, ensure compliance with universal opt-out signals like the Global Privacy Control, and align privacy notices with actual practices. Regulatory enforcement advisories and FAQs should be treated as essential readings to stay current on regulators' priorities. Likewise at the inaugural Atlanta AI Week, national security and ethical concerns came into sharper focus. Despite promises of localized data storage, some social media platforms and apps continue to raise alarms over foreign governments' potential access to personal data. While experts encourage experimentation and practical application of AI tools, they are also urging businesses to remain vigilant to threats such as deepfakes, AI-driven misinformation, and the broader societal implications of unchecked AI development. In this episode of She Said Privacy/He Said Security, Jodi Daniels, Founder and CEO of Red Clover Advisors, and Justin Daniels, Shareholder and Corporate Attorney at Baker Donelson, share their top takeaways from the IAPP Global Privacy Summit 2025 and the inaugural Atlanta AI Week. Jodi highlights practical steps for improving privacy rights request handling, the importance of regularly testing cookie consent management platforms, and ensuring published privacy notices reflect actual practices. Justin discusses the ethical challenges surrounding AI's rapid growth, the national security risks tied to social media platforms, and the dangers posed by deepfake technology. Together, Jodi and Justin emphasize the importance of continuous education, collaboration, and proactive action to prepare businesses for the future of privacy and AI.

Fresh out of Beaver Stadium, we discuss who and what stood out during Penn State football's Blue-White Game. There are several storylines to review, along with a Saturday commitment from Syracuse receiver transfer Trebor Pena. Enjoy complete Penn State coverage anytime at Lions247.com. Follow the team on X: @Lions247 @TDsTake @danieljtgallen @tyler_calvaruso @MarkXBrennan. Follow or subscribe to the Lions247 Podcast on Spotify, Apple Podcasts, Stitcher, or wherever you get your podcasts. And watch every episode on YouTube. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

In this deeply personal episode, Maggie shares her transformative experience attending a week-long Dr. Joe Dispenza meditation retreat. After struggling with chronic health issues for 18 months, she found herself immersed in a powerful environment of healing and connection. Maggie opens up about the challenges of intense meditation sessions, the beautiful community she discovered, and how this retreat pushed her beyond her comfort zone in unexpected ways. Whether you're familiar with Dr. Joe's work or simply curious about meditation's potential impact on health and mindset, this vulnerable conversation offers a glimpse into one person's journey through darkness into a more peaceful state. Click here to join vibe club  

Ever wonder what separates the Land Academy members who talk about success from the ones who make it happen? In today's episode of The Land Academy Show, Steven Jack Butala and Jill DeWit share the powerful real-life transformations happening behind the scenes—straight from recent consulting calls with ambitious Land Academy members. You'll hear stories of brand-new investors taking fast, focused action… seasoned pros making bold pivots to scale faster… and partners learning to streamline and delegate their way to $100K months. From spreadsheets to seller financing struggles, to 4am Zoom calls and website makeovers—this episode is packed with practical takeaways, inspiring wins, and a reminder that the right support can change everything. Whether you're just getting started or ready to level up, this one's for you.

BRONCO FOCUS EVERY MONDAY-FRIDAY AT 3:45 P.M.: Bob Behler, the voice of Boise State athletics, joins Prater and Mallory to share his impressions of Saturday's Spring Game at Albertsons Stadium. No. 1: Impressive performance from potential QB2 Kaleb Annett.See omnystudio.com/listener for privacy information.

BRONCO FOCUS EVERY MONDAY-FRIDAY AT 3:45 P.M.: Bob Behler, the voice of Boise State athletics, joins Prater and Mallory to share his impressions of Saturday's Spring Game at Albertsons Stadium. No. 1: Impressive performance from potential QB2 Kaleb Annett.

BRONCO FOCUS EVERY MONDAY-FRIDAY AT 3:45 P.M.: Bob Behler, the voice of Boise State athletics, joins Prater and Mallory to share his impressions of Saturday's Spring Game at Albertsons Stadium. No. 1: Impressive performance from potential QB2 Kaleb Annett.See omnystudio.com/listener for privacy information.

On this episode of Altitude Advantage, team reporter Elisa Hernandez and lead writer Aric DiLalla discuss their top takeaways from the pre-draft press conference of Head Coach Sean Payton and General Manager George Paton. Intro & value of continuity (00:00-2:30) Looking back at recent Broncos drafts (2:31-6:22) Strengths & weaknesses of the 2025 NFL Draft (6:23-9:55) How the trade market unfolds (9:56-13:02) Payton & Paton on drafting a running back in the first round (13:03-17:25) How the Broncos can help Bo Nix in the draft (17:26-21:24) Payton's evaluation of Broncos' wide receivers/wrapping up (21:25-24:57) Want more of “Altitude Advantage”? Subscribe on Apple Podcasts, Spotify, TuneIn, Stitcher or wherever you get your podcasts. Make sure to leave a rating and review or a comment if you're watching on YouTube.See omnystudio.com/listener for privacy information.

“You learn firsthand from us about our history, about our traditions, about why things are done in a certain way. Where we go as locals, which restaurants we go to, what we eat, what we do in our spare time. It's the art and the pleasure of giving, I feel very proud and honored and lucky to live where I live. And I want to share that experience with as many people as possible so they can take a little bit back with them wherever they go home to.”We're in great company with Mar Suau, the second-generation owner of Son Brull, a rural sanctuary of relaxed luxury in the heart of the Mediterranean. What was once an 18th-century monastery is now a Relais & Châteaux hotel and spa surrounded by vineyards, orchards, and olive groves—the quintessence of what is authentically Mallorcan. And for those looking to adventure beyond their stay, Mar is also the founder of The Ventourist, where she curates select active experiences across Spain and invites guests to go beyond Son Bull to discover the best of Spain—exploring incredible landscapes and uncovering local secrets.In this episode, Mar shares with us a peek inside an island life she has always known, yet one many of us only ever dream of—a truly genuine host with a humble pride and passionate responsibility as she considers the legacy she hopes to leave behind.   Top Takeaways[2:15] Born into hospitality, Mar was practically raised in hotels alongside her brothers—spending weekends and holidays in her father's properties, playing imaginary 'hotel' as a child, and watching guests return year after year as they became like family.[5:15] How a crumbling monastery captured Mar's father's imagination for years until fate finally allowed him to rescue this abandoned jewel—unveiling during renovation the whispered secrets and hidden treasures behind its walls. [9:25] As the last independent luxury hotel owned and operated by locals on an island increasingly claimed by international brands, Mar carries her family legacy forward with a bittersweet pride—honored to preserve genuine Mallorcan hospitality and hopeful for a more authentic future.[13:30] From dawn to dusk at Son Brull, guests drift between moments of peaceful solitude among the gardens to convivial encounters with local life.[17:45] Once sustaining monks with its bounty, Son Brull's rejuvenated land now flourishes again after decades of abandonment—from olive groves to orchards, beehives to vineyards—all creating a living tapestry inviting guests to embrace the timeless rhythm of Mallorcan terroir.[24:40] Through The Ventourist, Mar extends her hospitality beyond Son Brull's walls by crafting tailormade active journeys across Spain—all guided by her belief that sharing her homeland through local eyes is 'the art of giving,' allowing travelers to carry authentic pieces of Spanish life home.Visit For YourselfSon Brull Website | @sonbrull The Ventourist Website | @the_ventourist

Welcome to Hit the Brakes podcast, where the seasoned logistics professionals at Fetch Freight dive into the top stories, market trends, and can't miss topics about the supply chain. In this episode, Mitchell and Maggie Lewis discuss their top takeaways from the 2025 TIA Capital Ideas Conference. Please let us know if you have other questions to ask or topics to discuss! Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠fetchfreight.com⁠⁠⁠⁠⁠⁠⁠⁠⁠ and follow us onLinkedIn⁠⁠⁠⁠ and ⁠⁠⁠⁠Instagram.

What happens when creativity meets sharp market insight?In this episode, Raffic Aslam (ex-Creative Director at Zoho) breaks down the 3 campaigns that defined Zoho's global marketing playbook:1️⃣UAE VAT Campaign – A masterclass in cultural targeting that unlocked a new market via a single character: Kutty, the Malayali accountant.2️⃣ Made in India for the World – A bold declaration of Indian innovation for a global SaaS audience.3️⃣Super Bowl Ads – Frugal but fierce, this campaign helped Zoho stand out in a sea of enterprise giants.⏱ Timestamps00:00 – Introduction02:15 – The birth of the Zoho logo06:30 – Why simplicity & color made the logo unforgettable08:37 – Branding vs. Performance Marketing14:25 – Campaign 1: UAE VAT Campaign – Meet “Kutty”20:45 – Lessons from targeting expat accountants23:02 – Campaign 2: Made in India, Made for the World27:00 – Building pride in Indian-built software30:55 – Campaign 3: Zoho's Super Bowl Ad Strategy35:10 – How Zoho kept it frugal but memorable38:00 – Branding advice for SaaS founders41:20 – Final takeaways for startup marketers

“I like to say sometimes we are an analog experience. Everybody today is talking about digitalization, which is indeed important. But the digital means can never, ever replace the human connection between two people. We are artisans of memories. It's the software of our hotels. The hardware is in the beauty, how they look, but it would be completely empty and without soul if it was not about the people.”We're in great company with Ingrid Koeck, a Partner of Torel Boutiques in Portugal where her passion as an “Artisan of Memories” lies in crafting unique places. By infusing soul into remarkable structures with Portuguese artistry and interior design she intentionally creates a profound human connection with curious travelers turned guests.With a growing collection of prestigious Portuguese boutique hotels sprinkled across Lisbon, Porto, the Douro Valley and soon the Azores, Torel Boutiques embody excellence around every corner—from the service to the amenities, the gastronomy to the ambiance, the distinctive moments turned memories. In this episode, Ingrid's natural storytelling captivates us as she weaves a narrative of her own life's travels, painting for us a picture of the passion she found in Portugal, the home she created there, and the tales of cultural heritage she continues to capture in this convivial chapter. Top Takeaways[2:05] Ingrid's life is full of many colorful chapters—from growing up in her grandmother's rural Austrian bed & breakfast to spending a decade with the UN across Africa and the Middle East—a story where diverse cultures have shaped her profound curiosity of and appreciation for authentic human connection.[7:05] Through life's unexpected turns, Ingrid learned to balance her need for both adventure and stability—evolving from a fearless young traveler to seeking her European roots and creating her own hospitality business where meaningful connections happen on her terms.[12:15] Shaped by the resilient women in her family, Ingrid's defining traits of curiosity and courage allow her to embrace new challenges with the unwavering confidence that no matter what happens, she can always take care of herself.[20:05] Through Torel Boutiques' thoughtfully designed spaces, Ingrid honors her grandmother's wisdom that true hospitality creates memories based not on things, but on how guests feel when personally connected.[25:00] Celebrate a legacy of Portuguese royalty with Torel Palace Lisbon and indulge in Michelin star gastronomy at 2Monkeys.[25:35] Honor the writers of Portuguese literature with Torel Palace Porto and study your senses at BLIND.  [26:40] Discover a history of Portuguese expeditions with Torel 1884 and sip on a vault of fine wines at Bartolomeu Bistro & Wine.[27:40] Savor the heritage of Portuguese vineyards at Torel Quinta da Vacaria and taste the terroir at Schistó.[31:30] Craft artisanal traditions such as soap making at Torel Saboaria. [35:55] Embrace the timeless tranquility of Portugal through nature-inspired sanctuaries at Calla Wellness & Spa—from Douro Valley's wine therapy to Lisbon's exotic chocolate-infused sanctuary.[39:20] Uncover a hidden gem at Torel Terra Brava shining soon on the Azores Islands.Visit For YourselfTorel Boutiques Website Lisbon: @torelpalace_lisbon Porto: @torelpalace_porto | @torel1884 | @torelavantgarde | @torelsaboariaDouro Valley: @torelquintadavacaria Azores: @torelterrabrava

The world is completely different than it was before ChatGPT.

This week on GRIT: The Real Estate Growth Mindset, Brian Charlesworth is joined by Jace Gillies, team leader at Utah Life. They talk about growth, leadership, and building a team that performs with consistency. From closing 29 deals in his first year to now leading over 90 agents, Jace shares what it looks like to scale while keeping culture intact. Jace talks about his start in real estate, coming from warehouse work and having no idea how to write a contract. A quick ask for help turned into joining a six-agent team and earning six figures in year one. “I thought I couldn't make money on a team, but I had no idea what teams even offered,” he says. The conversation moves into Jace's transition from top producer to team leader and what it took to turn around the Salt Lake office. With systems missing and accountability lacking, Jace lost nearly half the agents in his first month. “They didn't want to work. They didn't want to be held accountable,” he explains. But with daily effort, recruiting, and buy-in, that office went on to close over $100M. Brian asks Jace about recruiting, and Jace shares the script and mindset shift that helped him add 31 agents in one quarter. He highlights how he uses social proof, automation, and consistent follow-up to find the right people. “I finally believed we were the best place for agents. Once I owned that, everything changed,” he says. They close out by discussing agent productivity and how Sisu plays a central role. From onboarding to coaching to contests, everything is built around tracking what matters. “I don't know how to coach without numbers. Sisu gives us everything,” Jace adds. Top Takeaways: (4:16) Value of teams & shifting mindset (9:35) Taking over the salt lake office  (14:09) Mental shift in recruiting (18:24) Tracking for predictable closings (25:57) Sales contests & team culture (29:50) Leading by example in real time (33:26) Impact of sisu on everything If you're a team leader looking for structure or an agent trying to grow without guessing, this episode is packed with examples of how to do both. Tune in now!  About Jace Gillies Jace Gillies leads the Salt Lake City expansion at Utah Life Real Estate. He entered the industry five years ago and now oversees sales for the entire team. Using Sisu, Jace coaches agents, tracks performance, and drives recruiting. His focus is on building a team where growth and results stay consistent.   Connect with Jace: LinkedIn

Welcome to Insiders Rewind — Recapping March!   This month, we're diving into insights from Episodes 216 to 219, covering everything from Agent AI to tax strategies, growth challenges, and flipping business models for success!   Ep. 216: Agent AI Playbook for Service Business Owners — Discover how Agent AI works autonomously and integrates with your systems for true automation. Ep. 217: Taxes 101 — Dan and Donnie share tax tips and how to avoid common pitfalls for pest and lawn business owners. Ep. 218: The GreenPal Story — Brian Clayton explains why he built GreenPal for lawn care pros, not homeowners, and why it worked! Ep. 219: Creating Cohesion — Donnie talks about managing team growth and navigating when great employees can't keep up.   We'd love to hear from you. Drop a comment, leave a review on Apple Podcasts or Spotify, and connect with us on social media @PMPIndustryInsider.

“Culturally, it's so important because a lot of experiences are just the same all over the world. Hotels, theaters, cinemas, music—it's so mainstream today that we all consume pretty much the same thing. But culinary-wise, there's still this chance to create and cook something that's so local on the level of experience that you can really understand and feel the landscape, the seasons, the culture, and the history of the country. So I'm super happy to be in that field because I think we're one of the last kinds of handcrafts that are still very present in the city.”We're in great company with Niklas Ekstedt, the Swedish Chef famously known around the world for reigniting the ancient way of cooking over fire in Scandinavia at his restaurant Ekstedt in Stockholm, where he has been recognized by The Best Chef Awards and a recipient of a Michelin Star. After an acclaimed culinary career as a young chef, Niklas found himself returning to his roots, curiously unearthing forgotten techniques and a sophisticated Scandinavian culinary heritage that challenged the Mediterranean supremacy he felt ready to challenge. What may have started as a small spark in his fire-forged restaurant ultimately created a movement where ancient methods meet modern gastronomy.In this episode, Niklas warmly welcomes us to savor a taste of this nearly lost artform, sparking our curiosity about what other ancient rituals we should unearth and giving us the courage to begin our own adventures. Top Takeaways[2:50] Amid the forests of northern Sweden, young Niklas's tastes were shaped by Sámi playmates, parents who embraced nature's bounty, and wilderness that would one day call him back to cooking by fire.[5:05] From his rural roots to culinary stardom, Niklas traveled through Chicago kitchens, befriended René Redzepi in Copenhagen, trained at legendary elBulli, then returned to Sweden where, barely into his twenties, he opened his first restaurant and was met with celebrity chef status…that is before he discovered his true flame.[9:30] In a secluded island kitchen outside Stockholm, Niklas found himself captivated by primitive cooking methods, discovering a forgotten Nordic culinary sophistication that would become the foundation of his revolutionary fire-forged restaurant.[16:05] Stepping into Ekstedt, guests embark on a primal sensory journey where crackling flames illuminate the darkness, birchwood smoke perfumes the air, and the kitchen's ancient fire elements transform seasonal Nordic ingredients into dishes that evoke both a forgotten past and an innovative future, creating an experience that transcends mere dining to become a connection with Sweden's culinary heritage.[25:20] Niklas continues to foster community through Tyge & Sessil, an intimate space celebrating hidden gem natural wines, and Hillenberg, a neighborhood brasserie where humble Scandinavian cooking creates an accessible entry point to his Nordic culinary philosophy. [28:00] See Stockholm through Niklas's eyes—travel metro stations turned art installations, discover museum treasures without spending a krona, go island hopping by boat, and embrace the Swedish “Allemansrätten” right to roam.Notable Mentions Charlie Trotter's in ChicagoNorwegian explorer & writer, Thor Heyerdahl's Kon-Tiki expeditionSkepparholmen Nacka outside Stockholm“Kardemummabullar” traditional Swedish Cardamom Buns for a daily “Fika” Alice Waters, pioneer of the “farm-to-table” movement in AmericaA Taste From AfarCookbooks by Niklas EkstedtEkstedt: The Nordic Art of Analogue Cooking Food from the FireScandinavian ClassicsHappy FoodVisit For YourselfEkstedt Website | @ekstedtrestaurant | @niklasekstedt

Jack and Aram discuss Lenny, MIT, and bat dimensions before walking through the good and bad of MLB's Opening Weekend.0:00 Intro3:31 Torpedo Bats13:35 Colton Cowser15:13 Roman Anthony20:20 Rafael Devers23:30 Roki Sasaki30:38 Max Muncy35:10 Oneil Cruz39:47 David Bednar41:38 Aaron Judge45:22 Jazz Chisholm47:32 Otto Lopez50:36 Griffin Conine51:47 Max Meyer53:02 Jesus Luzardo55:09 Ryan PepiotJoin Our New Discord! - $5 off the first month!Subscribe to Our New Newsletter!Check out our LinkTree!Get Your Just Baseball MerchUse Code "JUSTBASEBALL" when signing up on BetMGMSupport this podcast at — https://redcircle.com/the-just-baseball-show/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

The Lions247 Podcast returns with feedback from a James Franklin press conference and Penn State's first spring practice. We also preview PSU Pro Day, then spotlight the Nittany Lions' newest commit and campus visitors. Enjoy complete Penn State coverage anytime at Lions247.com. Follow the team on X: @Lions247 @TDsTake @danieljtgallen @tyler_calvaruso @MarkXBrennan. Follow or subscribe to the Lions247 Podcast on Spotify, Apple Podcasts, Stitcher, or wherever you get your podcasts. And watch every episode on YouTube. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

“And so all of our activities, all of our food, all of our ethos gets you to a place of just absolute peace. With that peace, you can find whatever it is that you're needing to break through. And once you break through, you can serve more than just your own problems. You can start solving these problems in the world.”We're in great company with Britnie Faith Turner, the Founder and Owner of The Aerial, BVI, a private island experience with the best views in the British Virgin Islands that acts as a force for good. What appears as an all-inclusive eco-resort goes well beyond just that—serving as an incubator for positive transformation, delivering a never-before-seen kind of luxury for its guests.Yet The Aerial, BVI is only a small piece in Britnie's larger plan to build numerous businesses that are for purpose, not for profit. As Britnie tells of the serendipitous beginnings of each, the story reveals a theme of elevating people and places through the pursuit of excellence.  In this episode, as we celebrate Women's History Month around the world, Britnie encourages us all to travel the world and discover our own ‘Aerial'—that higher perspective where we realize we are a part of something bigger than ourselves.  Top Takeaways[2:00] From humble beginnings living in her car while working for free, Britnie developed an eye for excellence—as she witnessed third-world poverty alongside first-world despair, realizing her mission would take her far beyond material success.[4:50] How an unexpected vision led Britnie to turn from mindful revitalization of dangerous neighborhoods to journey to find an island sanctuary where she would invite visitors to awaken their own transformational potential. [10:10] Britnie grew up self-admittedly hating wealthy people, yet before long, she sought out to surround herself with some of the richest people on the planet—finding this sense of discomfort and dreaming contagious.[15:00] Buying and building on a private island is not as easy as one might imagine—and yet even through a devastating divorce, two category-five hurricanes that annihilated the BVI, and a grand opening that coincided precisely with the global COVID-19 pandemic, Britnie's faith was unwavering.  [24:15] Inspired by personal passions, chance encounters, and loved ones, Heal the Heroes transforms troubled veterans and first responders into humanitarian operators—creating an 'army of good' that has rescued over 8,400 people from trafficking and disasters. [30:25] From sunrise to sunset, The Aerial, BVI captures the sacred healing properties of the Island—sharing it with guests through locally sourced cuisine, uniquely created accommodations, and an abundance of wellness activities. [35:20] Why “Purpose Luxury” is the perfect blend of excellence and impact, and how the future of luxury travel provides those who have everything and yet nothing, with the one thing that some seek and everyone deserves—peace.  Notable Mentions The Virgin Way by Richard BransonRedemption RanchElevate SummitsVisit For YourselfThe Aerial, BVI Website | @theaerialbviAerial Recovery Website | @aerialrecoverygroupBritnie Turner Website | @britnieturner

"The feeling I hope people will have on this farm is that deep sense of safety and surrender. The feeling of being deeply nurtured and nourished. That feeling you get from visiting your great aunt or your grandmother. That one elderly female family member where you go when you just want to be deeply nourished and you feel completely at ease and safe. All your worries just sort of dissolve instantly.”We're in great company with Fleur and Nicole, partners in life and in profession who serendipitously found and meticulously stewarded Sterrekopje Farm in South Africa, a biodiverse farm and soulful sanctuary where curiosity blooms, creativity flourishes, and laughter is ever-present.Here, they have carefully curated a community of chefs, farmers, holistic practitioners, and artists to share, teach and connect with guests– in an environment where every ritual, every bite, every breath is a chance to celebrate the gifts of Mother Nature, from 'soil to soul'.In this episode, as we celebrate Women's History Month around the world, Nicole and Fleur share with us their serendipitous story, their thoughtful travel tastes, their everyday rituals—providing us with the fertile ground and nourishing energy we crave to pursue our own dreams and desires. Top Takeaways[1:45] A story of how two Dutch women, since early childhood, fell in love with travel to cultures beyond their familiar Western world and how a serendipitous flight became fate that would lead them on their next big adventure together. [6:30] How Nicole knew Sterrekopje Farm, ‘the bright star above the little mountain,' was the sanctuary she had been searching for—a beloved family farm dating back to the 17th century that once produced wine and olives and was in need of nurturing back to health. [10:15] Over the course of five years, Nicole and Fleur have grown alongside the farm itself—transforming monoculture into biodiversity, harvesting their first honey, and witnessing a beautiful season of abundance that extends beyond the land to the guests who visit—which today flourishes as a wild, fertile sanctuary.[13:20] Nicole reminds us all, “What is so important is to get people out of their heads and into their bodies because we're living so much in our heads these days. And to really connect with your body—that opens the ability to connect to other people, but also to yourself and to nature.”[16:50] Close your eyes and listen as Fleur transports us all to a day in the life at Sterrekopje Farm, painting a stunning picture with a palette of serene senses. [22:00] What some may call “a beautiful mess,” is intentionally a curated collection of fabrics and antiques from a multitude of cultures—creating not a standard hotel with sterile rooms, but a soulful place with personal sanctuaries.  [27:20] Discover what makes Sterrekopia a playground for adults to relearn the art of play—a place where curiosity and creativity blossom.[32:20] Here, ‘farm to table' tastes more like ‘soil to soul' as Nicole and Fleur invite their guests to satiate conscious indulgences and savor communal dining experiences.Notable Mentions Jennica Arazi of Marbella Club in SpainVisit For YourselfSterrekopje Farm Website | @sterrekopjefarm

Episode Overview:This week's episode is absolutely buzzing — and not just because we're talking bees. Meet Emma: ethical beekeeper, skincare alchemist, and proof that you don't need GCSEs or a conventional path to build something extraordinary. From being a teen mum navigating the stigma, to cold-calling for dodgy kitchen companies (yep, we went there), Emma's journey is anything but beige.She's built a legacy from raw honey and raw grit, and if you've ever thought your life was too messy to build something meaningful — think again. Emma proves that the wildest journeys often make for the sweetest success.Think success looks like a neat CV, a degree, and a 5-year plan?Wrong. Sometimes it looks like telesales in a smoke-filled office, accidental skincare breakthroughs in your kitchen, and bee stings to the face.

“Arthur went to Dublin and he used the 100 pounds to pay for the 9000 year lease in St. James's Gate. So when you go to the storehouse in Dublin now, you'll see that the first 10 years of his brewing career in Dublin was brewing an ale, and that was the ale that his father taught him in Cashel. If it was not for the Archbishop of Cashel, we would not have Guinness. And therefore, we consider ourselves the Godfather of Guinness.”We're in great company with Adriaan Bartels, the award-winning General Manager of Cashel Palace, a magnificent regal manor in the bountiful heart of Ireland, Tipperary's Golden Vale. With origins in the 18th century, the manor is meticulously restored and exquisitely reimagined as a five-star luxury hotel, enveloped in nature and overlooked by ancient history.Here, a tapestry of timeless hospitality, proud Irish heritage, and sustainable modern practices are seamlessly woven together for guests to experience Cashel Palace in all its glory – from its notable thoroughbred horse breeding ties to its acclaimed humble beginnings of Guinness.   In this episode, Adriaan reminds us what it is about our ties to and dreams of Ireland – from the rich soil to the flowing spirits to the convivial music – that inspire so many of us to paint the world green on St. Patrick's Day. Sláinte!Top Takeaways[2:45] How Irish hospitality thrives on genuine curiosity, with locals eagerly connecting you to their world by finding those delightful threads that make strangers feel like distant family.[6:40] From archbishops to aristocracy, from country leaders to leading ladies, from a hundred pounds to the first Guinness pints, Cashel Palace boasts a rich and illustrious history of notable hospitality dating back to 1732. [10:20] Adriaan learned to wear many hats during Cashel Palace's transformation – at one moment an architect, the next an interior designer, soon after a general manager – all the while learning to balance Irish traditions and heritage with innovation for modern travelers and times. [19:45] Watch and listen as Cashel Palace transforms from a buzzing hub of daytime activity and attentive service to an intimate evening retreat complemented with fireside drinks, creating the perfect atmosphere for guests to unwind.[23:40] Local produce and purveyors are always in season at Cashel Palace as their commitment to sustainability sets the table for some of Ireland's most flavorful bounty – from the native Irish bee's wild honey to the centuries-old mulberry tree's fruit jam.[28:50] Cashel Palace is the crown jewel of the equine world and its owners, The Magnier Family, have been at the very heart of Ireland's rich tapestry of thoroughbred racing and breeding legacy for generations – which is why they invite guests to experience exciting programming and exclusive access to some of the most prestigious racing farms in the world.[32:30] From Cashel Palace's doorstep, Tipperary's Golden Vale reveals its soul through untouched small-town authenticity – ancient pubs with crackling fires and quaint shops nestled in a landscape that captures Ireland's timeless pastoral beauty.[35:40] For those travelers seeking a climate sanctuary growing rarer in our warming world, you might just discover that the true pot of gold at the rainbow's end is Ireland's emerald-green landscape.Notable Mentions Rock of CashelThe Story of GuinnessGuinness Brewery, DublinCoolmore Stud and BallydoyleLarkins Bar & Restaurant on Lough DergMikey Ryan's Bar & Kitchen Donoghue's Traditional Irish BarThe Origins of HalloweenSkellig Michael Island from Star Wars Visit For YourselfCashel Palace Website | @cashelpalace Give the Palace a Call | +3536262002

In this episode of Full Disclosure, hosts Tyler Traudt and Nina Enholm sit down with Mark Vitner, Chief Economist at Piedmont Crescent Capital, for an in-depth economic update. Mark unpacks key trends shaping the U.S. economy, analyzing the impact of tariffs, Federal Reserve policy, and shifting supply chains on growth and inflation. With years of experience forecasting economic conditions, Mark provides valuable insights into the current slowdown, explaining how uncertainty in trade policy and capital investment decisions is influencing business strategy. He breaks down the real effects of tariffs on consumer prices and how the Federal Reserve is managing inflation while avoiding recession. During the episode, you'll gain a deeper understanding of how economic conditions are evolving and what to watch for in the coming months, from potential rate cuts to shifts in housing and manufacturing. If you're looking for an analysis of where the economy is headed, this is an episode you won't want to miss. Featured Guest:  Mark Vitner is the Chief Economist at Piedmont Crescent Capital, where he provides strategic economic insights and forecasting for clients across industries. With over 30 years of experience in economic analysis, Mark specializes in assessing U.S. and regional economic conditions, financial markets, and geopolitics, with a focus on their impact on consumers, local economies, housing, and commercial real estate. Before founding Piedmont Crescent Capital, Mark spent nearly three decades at Wells Fargo as a Managing Director and Senior Economist, where he led macroeconomic research and regularly briefed corporate leaders, investors, and policymakers. His expertise also extends to roles at Wachovia, First Union National Bank, and Barnett Bank, where he developed strategic economic outlooks and provided critical analysis for financial institutions. Mark is a recognized thought leader in economic forecasting and has been a frequent speaker at industry conferences, corporate events, and policy discussions. He has also contributed to numerous publications on inflation, monetary policy, and economic development.  Top Takeaways from Episode 03: Tariffs & Trade Policy Impact – Tariffs can distort supply chains and increase costs, but their inflationary impact is often overstated. The long-term effects depend on whether they're used for revenue generation, trade leverage, or reshoring efforts. The Federal Reserve's Balancing Act – The Fed faces the difficult task of cutting rates to sustain growth while avoiding a resurgence of inflation. Mark predicts three rate cuts in 2025 but sees potential rate hikes resuming in 2026. Federal Debt & Fiscal Concerns – Interest payments on national debt have surpassed defense spending, raising long-term concerns. Future policy shifts may focus on entitlement reform, tax policy adjustments, and government efficiency to curb deficits.

In this episode of GRIT: The Real Estate Growth Mindset, Brian Charlesworth sits down with Leo Pareja, CEO of eXp Realty, to talk about the journey from selling nearly 4,000 homes to leading one of the fastest-growing brokerages in the industry. Leo shares how he started in real estate at 19, thinking he would be an investor, and ended up becoming one of the top agents in the country. Leo dives into how market cycles shaped his career, from making over $300,000 as a college student to nearly going bankrupt during the 2008 financial crisis. He explains how those experiences taught him to adapt and build resilience. "I thought I was that good. I wasn't. I was just in a bubble," he admits. He also shares how these lessons now influence his leadership at eXp, where he focuses on staying ahead of industry shifts. The conversation explores what it takes to scale in real estate. Leo talks about how he built one of the first teams doing over $100 million in sales and why understanding unit economics and market timing made the difference. He explains how the best agents and teams today are focusing on efficiency, lead generation, and knowing their numbers. As CEO, Leo is now leading eXp 2.0, a new phase of the company focused on making everything faster, smoother, and more agent-centric. He breaks down how eXp is investing in better technology, faster payments, and deeper agent support to stay ahead. "My goal is to deliver so much value that it's silly not to be with us," he says. Leo also gets personal, sharing how he prioritizes family and work-life balance despite a demanding role. He tracks time with his kids, blocks out non-negotiable time for them, and keeps his schedule tight. "90 percent of the time you'll spend with your kids is before they turn 18. Make it count," he shares. Top Takeaways: (1:53) Leo's real estate and tech journey (6:22) Entering tech at the worst possible time (8:32) The first big real estate win (10:19) The two ways to scale in real estate (11:27) Why should agents not copy top producers? (13:38) The importance of relationships (19:15) Why eXp changed everything (20:49) Why franchises are dying (21:53) What makes eXp 2.0 different? (24:54) Real estate market growth predictions (27:43) What agents should focus on now (29:42) Adapting to change in business (31:08) Controlling your own success   Don't miss this episode if you want insight into scaling a business, navigating market cycles, and building a real estate career that lasts. Tune in to hear Leo's perspective on the future of the industry and how the right mindset can make all the difference. About Leo Pareja Leo Pareja started his real estate career at 19 and became the #1 Keller Williams Agent worldwide by 28. Over 15 years, he sold around 4,000 homes before co-founding Washington Capital Partners in 2012, which grew into one of the largest private lending firms on the East Coast. In 2016, he co-founded Remine, a real estate tech platform that reached 80% market share and over 1.1 million users.  After exiting both companies, he joined eXp Realty's leadership team and now serves as CEO. He has been featured in the Swanepoel Power 200 and co-founded the Pareja Family Foundation, providing scholarships for women and minorities to enter the tech industry. Connect with Leo: Website LinkedIn

VideoNuze's conference last week, which focused on the intersection of CTV and AI, included valuable insights from 18 speakers in 5 sessions. We highlight the top takeaways.

“I think we're right where we want to be. People say to me, ‘You've succeeded in hospitality. What's your next project? What do you want to do?' And I said, ‘No, this ranch is a diamond and I'm just going to continue to polish it.'”We're in great company with Jim Manley, the Dreamer behind and Owner of The Ranch at Rock Creek, an award-winning all-inclusive ranch destination set amidst Montana's unspoiled beauty that preserves the spirit of the Wild West, while celebrating nature's bounty.It all started with young Jim Manley's Wild West obsession that took him from Wall Street success on a 20-year quest that finally materialized as The Ranch at Rock Creek—proving some childhood dreams refuse to fade with time.Today, Jim chooses to share that dream with his worldly guests, which has matured into the world's first Forbes Travel Guide Five-Star and Relais & Châteaux ranch—expanding the frontiers of experiential travel, or as he coins it, “adults at play.”In this episode, Jim shares with us why he believes the best souvenir is a great story, one that's lived and not just bought. Top Takeaways[1:30] How it all started for Jim as a child, hypnotized by cowboys galloping across his TV screen in a cramped New Jersey home, sparking a dream that he carried with him into adulthood. [4:30] It would take 20 years of searching, a long list of criteria, many doubters, and yet even more patience and perseverance, before Jim found an old mining and cattle ranching pocket of Philipsburg, Montana that would become The Ranch at Rock Creek.[9:40] Rejecting the beachside boredom of traditional getaways, Jim set out to create America's only truly inclusive luxury ranch—where adults rediscover their playful spirits through countless activities—all without the interruption of constantly opening their wallets. [20:05] What is “high end ranch food,” you ask? While it's not fussy, it is certainly local and seasonal, fresh and quality—best paired with good conversation in great company around the table. [24:30] Sustainability has taken root since The Ranch at Rock Creek's inception, and it only grows stronger over time—from local sourcing to community engagement, from eliminating single use plastics to encouraging guests to embrace walking and biking about the land. Visit For YourselfThe Ranch at Rock Creek Website | @theranchatrockcreek Give the Ranch a Call | 1.877.786.1545

“I would suggest getting lost. I would suggest getting lost on the small inland roads to discover the breathtaking views, the old abandoned villages, the endless fields of lavender, just to wander around.  And I would actually do the same with the boat. So I would also get lost in the multitude bays, and go to the local fisherman's restaurant because he will do his best to give you the best fresh fish that he caught that morning.”We're in great company with Maud Truchi, the visionary behind and proud owner of Maslina Resort, her love letter to the Mediterranean inspired by the astonishing landscape, authentic people, and untouched cultural heritage she found on the Croatian island of Hvar.  When Maud stepped foot on the island of Hvar for the first time after her own worldly travels and successful career, she realized this was the place of her childhood dreams - a place she desired to call home, create a hotel, and welcome travelers to discover what mindful luxury in the heart of the Mediterranean may feel like.In this episode, Maud shares her admiration and appreciation for this genuine sense of place and its people - inviting us all to come and live a meaningful experience that will broaden our horizon and open our minds.  Top Takeaways[1:45] From the beginning, Maud has traveled the world - collecting rich experiences and cultivating deep friendships - that have inspired who she is and what she creates today. And yet, her biggest lesson along the journey remains having a ‘lighthouse' to always guide her back home.[7:00] Was it the unspoiled beauty of nature, the genuine warmth of the people or the villages frozen in time, that left Maud breathless? Perhaps it was the blend of the three that called Maud to want to create something meaningful, yet preserve and protect something original.[12:20] “ I really realized then, that something bigger than me was created. Because you can only do as much as you can, but then you cannot make people feel good. They feel good because of everything that surrounds them. I think that when you are true to yourself and are authentic, at the end of the day, they feel it.”[16:00] From sunrise yoga stretches to sunset cocktails paired with endless views of the sparkling Adriatic Sea, guests flow through their day with mindful moments of wellness, seaside swimming, and dining under the stars - creating a natural rhythm that invites them to truly unwind.[21:30] Wellness is around every corner and engrained in every experience at Maslina Resort - inspired by the heritage of healing and Mediterranean lifestyle found on Hvar.[24:45] The “Mediterranean Diet” is not a fad, it is a way of life on the island of Hvar - with the seasonal produce and fresh caught fish, the onsite olive orchards and local vineyards influencing the daily menu, not the other way around. [30:50] The future for Maud and Maslina Resort is centered around mindfulness - mindful luxury, mindful growth, mindful experiences, mindful sustainability, mindful mentorship - only continuing to evolve in a slow yet nurtured way. Notable MentionsEl Nido Resorts, PhilippinesCOCO-MAT MattressesNohrd Fitness EquipmentAger, Stari Grad Plain, UNESCO World Heritage SiteGregada, Croatian Poached FishPeka, Croatian Veal DishExplore River Cetina, Brač Island, Split, OmišDiana Popescu of Epoque Hotel, BucharestAdine Roode of Jabulani Safari, South AfricaLaure Pertusier of Saint James Paris, FranceShan Varty of Londolozi, South AfricaVisit For YourselfMaslina Resort Website | @maslinaresort

Want to become a recognized thought leader and scale your impact? In this episode, I sit down with Sara Connell, a five-time best-selling author and founder of the Thought Leader Academy, to uncover the secrets to standing out in a noisy world.Top Takeaways from This Episode:The Power of Storytelling—why YOUR story is the key to impact & influence.The 3-Step Thought Leader Formula to achieve big goals & break subconscious blocks.Neuroscience & Success—how anchor images can rewire your brain for achievement.The 7 Doors of Opportunity—how writing a book can skyrocket your credibility & revenue.Creating a Ripple Effect—why stepping into leadership isn't just about you—it's about those you inspire!Unlock YOUR path to becoming a thought leader!FREEBIE! Looking to write your own best selling book? Check out Sara's "7 Steps to Write a Revenue Generating Bestselling Book": https://www.saraconnell.com/7-steps-to-write-a-revenue-generating-bestselling-bookWatch episodes on YouTube and subscribe to our channel!https://www.youtube.com/@letsgowin

“If you go to buy a beautiful men's suit from a famous brand, you can go to Tokyo, New York, London or in Rome, and it would be the same because it's a brand, okay? So why do you travel? But in Florence, you go to a great tailor who will do a beautiful suit. You decide the textile, you decide the buttons and all the details that you love. And this is a unique piece just for you. And this is what we create every day, for every guest, in a different way. This is the sense of place.”We're in great company with Claudio Meli, the General Manager of The Place Firenze and Michela Babini, the Director of The Place of Wonders Foundation, who together, are tailoring their spirit of hospitality and their curated senses of the guest experience for a new generation of immersive travelers, dedicated to promoting and preserving the heritage of Italian craft. Here, The Place Firenze extends a warm Tuscan welcome, well deserving of their international awards and recognitions as a timeless classic reinventing made-to-measure hospitality - where every detail is inspired by the enduring beauty and traditional artisanship they are proud to have in their beloved city. In this episode, Claudio and Michela delight in the tales and testimonials that continue to unfold as they create a new home for us as travelers to visit in Florence - while curating the next generation of artisans and makers molding Italian craft into a modern day Renaissance.    Top Takeaways[3:40] What makes The Hospitality Experience one precious thread woven between hospitality and experience, one family with a long history of curating hotels, one collection of new ideas? Three hotels strongly rooted in remarkable places - Londra Palace in Venice, Borgo dei Conti in Umbria, and The Place Firenze. [4:50] Claudio's love for Florence radiates as he shares stories of his beloved city - a rare treasure where Renaissance masterpieces line the streets and Tuscan vineyards roll just beyond, creating an enchanting blend of art and terroir that has inspired generations.[18:10] The Place Firenze is “deeply connected to its daily life, artistic heritage and lively cultural scene in this vibrant Tuscan city,” from the Scagliola tabletops to the Ginori porcelain table settings, from the Pamploni engraved silver glasses the Spaghetto al Pomodoro and Negroni Experience savored in such company.  [28:30] Michela's passion speaks for itself as she shares how The Place of Wonders Foundation breathes life into Italy's cultural heritage by connecting curious travelers with master artisans in Florence, Venice, and Perugia, while nurturing the next generation of craftspeople through dedicated scholarship programs. [32:50] From designing zero kilometer sneakers in Florence to molding glass beads in Murano to weaving on ancient looms in Umbria - the foundation is creating an immersive journey for travelers and the next generation of makers alike - where traditional techniques meet contemporary innovation in workshops that have shaped Italian artistry for centuries.[41:15] Both Claudio and Michela agree there is so much left to be discovered in and around Florence, but it will take a future with more guests seeking slow travel, slow food, and slow moments, to really uncover those hidden gems. Notable MentionsFabbri Pasta ArtigianaleLaudemio Olio Extravergine Di Oliva Fattoria di Maiano Piazzale MichelangeloView from the Church of San MiniatoTrattoria Sergio GozziSanto Spirito or the “Oltrarno” on the other side of the ArnoRistorante La GiostraMuseo del NovecentoCastello di Ama Chianti WineryVisit For YourselfThe Place Firenze Website | @theplacefirenzeThe Place of Wonders Website | @theplaceofwonders.foundationThe Hospitality Experience Website | @the.hospitality.experience

Check out my latest Shift Today with Alison Video YouTube episode, Intuitive Takeaways from a Recent Getaway that I had with Pam Sherman.I share my Top five Takeaways and examples of how you can expand your intuition. Plus, at the end of the video, I share some photos and videos of the sweet sea lion Brightbill we rescued, along with a unique rainbow. Enjoy!There are 5 Top Takeaways that I share1) If it feels right, it's your intuition celebrating you.2) No expectations create adventure.3) I no longer live in the past. I live in the now!4) We all have our own pace.5) You never know unless you take a chance.Happy DayAlison Schuh HawseyDonate to The Marine Mammal Center to support Brightbill's care. Thank you!Shift today into a greater tomorrow...@alisonschuhhawsey

The Big 12 football 2025 schedule dropped on Tuesday and Heartland College Sports' Pete Mundo shares his top takeaways from next fall's Big 12 football schedule!Privacy & Opt-Out: https://redcircle.com/privacy

Jinger Duggar Vuolo joins Kirk Cameron to discuss her new book "People Pleaser," and she shares why it's important that we focus on pleasing God and not others. She also details how to be more aware of what is driving people pleasing behavior and how to break unhealthy bonds with seeking the approval of others. Don't miss this insightful discussion here on Takeaways with Kirk Cameron on TBN! Missed the last episode? Listen in as Dr. Henry Cloud discusses strategies for successfully handling difficult conversations. WATCH Takeaways with Kirk Cameron episodes for free on TBN+! Each episode of Takeaways with Kirk Cameron features knowledgeable guests having a respectful and thoughtful conversation surrounding topics that are impacting our society every day. Kirk's hope is that you will walk away from this show with practical steps on how to better your family, your community, and your nation. Learn more about your ad choices. Visit megaphone.fm/adchoices

In today's episode, Kyle Grieve is joined by co-host Clay Finck to summarize key learnings from 2024. We chat about the importance of focus and avoiding confusing noise, data that shows how difficult individual stock picks are to succeed in, why you should welcome disconfirming evidence, the impermanence of seemingly impenetrable businesses, how to close feedback loops to ensure investments are on the right track, the importance of being trustworthy and reliable, and much more! IN THIS EPISODE YOU'LL LEARN: 00:00 - Intro 03:11 - Why investors need to focus on the things that matter and how to avoid spending time on noise. 09:19 - Why investors should be aware of the base rates of success of investing in individual stocks (hint, making money is a lot harder than you think). 25:42 - How you can utilize and search out disconfirming evidence to improve your thinking processes. 29:46 - The impermanence of business success and the importance of updating your thinking when new information becomes available. 33:00 - The three sources of investing returns that drive the performance of a stock. 42:53 - How to use punctuated equilibrium to be active at the correct times and inactive at the proper times. 50:52 - Critical lessons on how to close feedback loops for long-term investors. 1:00:29 - How to utilize the "cone of uncertainty" to signal conviction in great ideas. 1:02:49 - Why a great business can still have times of high uncertainty. 1:07:00 - The importance of being trustworthy and reliable. And so much more! Disclaimer: Slight discrepancies in the timestamps may occur due to podcast platform differences. BOOKS AND RESOURCES Join the exclusive TIP Mastermind Community to engage in meaningful stock investing discussions with Stig, Clay, Kyle, and the other community members. Listen to Clay's interview with Chris Mayer here | YouTube Video. Listen to Clay's interview with Hendrick Bessimbinder here | YouTube Video. Listen to William Greens' interview with Bryan Lawrence here | YouTube Video. Listen to Clay's interview with Morgan Housel here | YouTube Video. Listen to Clay's interview with John Huber here | YouTube Video. Listen to Kyle's review of What I Learned About Investing From Darwin here | YouTube Video. Listen to Kyle's interview with Annie Duke here | YouTube Video. Listen to Kyle's review of the Nomad Partnership Letters here | YouTube Video. Listen to Stig's interview with Mohnish Pabrai here | YouTube Video. Follow Kyle on Twitter and LinkedIn. Check out all the books mentioned and discussed in our podcast episodes here. Enjoy ad-free episodes when you subscribe to our Premium Feed. NEW TO THE SHOW? Follow our official social media accounts: X (Twitter) | LinkedIn | Instagram | Facebook | TikTok. Check out our We Study Billionaires Starter Packs. Browse through all our episodes (complete with transcripts) here. Try our tool for picking stock winners and managing our portfolios: TIP Finance Tool. Enjoy exclusive perks from our favorite Apps and Services. Stay up-to-date on financial markets and investing strategies through our daily newsletter, We Study Markets. Learn how to better start, manage, and grow your business with the best business podcasts. SPONSORS Support our free podcast by supporting our sponsors: River Toyota 7-Eleven Connect Invest Bluehost The Bitcoin Way ReMarkable SimpleMining American Express Public Fundrise Toyota Onramp Vanta Shopify HELP US OUT! Help us reach new listeners by leaving us a rating and review on Spotify! It takes less than 30 seconds, and really helps our show grow, which allows us to bring on even better guests for you all! Thank you – we really appreciate it! Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://theinvestorspodcastnetwork.supportingcast.fm